Kwadwo Fosu

Mr. Kwadwo Fosu

Department of Biochemistry, Cell and Mol. Biology, University of Ghana, Accra, Greater Accra, Ghana
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
STSeth Twum
Seth Twum
KFKwadwo Fosu
Kwadwo Fosu
RFRobin A. Felder
Robin A. Felder
KSKwabena A.N. Sarpong
Kwabena A.N. Sarpong
The African Journal of Laboratory Medicine focuses on the role of the laboratory and its professionals in the clinical and public healthcare sectors, and is specifically based on an African frame of reference.

19 July 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JQJude Tetteh Quarshie
Jude Tetteh Quarshie
KFKwadwo Fosu
Kwadwo Fosu
NONicholas Awuku Offei
Nicholas Awuku Offei
ASAugustine Kojo Sobo
Augustine Kojo Sobo
OQOsbourne Quaye
Osbourne Quaye
AAAnastasia Rosebud Aikins
Anastasia Rosebud Aikins
Colorectal cancer (CRC) is the third most frequent cancer and the second leading cause of cancer-related deaths globally. Evidence shows that over 90% of CRC cases are initiated by a deregulated Wingless Integrated Type-1 (WNT)/β-catenin signaling pathway. The WNT/β-catenin pathway also promotes CRC cell proliferation, stemness, and metastasis. Therefore, modulators of the WNT/β-catenin pathway may serve as promising regimens for CRC. This study investigated the effect of cryptolepine—a plant-derived compound—on the WNT/β-catenin pathway in CRC. Two CRC cell lines, COLO205 and DLD1, were treated with cryptolepine or XAV 939 (a WNT inhibitor) in the presence or absence of WNT3a (a WNT activator). Using a tetrazolium-based assay, cryptolepine was found to reduce cell viability in a dose- and time-dependent manner and was a more potent inhibitor of viability than XAV 939. RT-qPCR analyses showed that cryptolepine reverses WNT3a-induced expression of β-catenin, c-MYC, and WISP1, suggesting that cryptolepine inhibits WNT3a-mediated activation of WNT/β-catenin signaling. Cryptolepine also repressed WNT3a-induced OCT4 and CD133 expression and suppressed colony formation of the cells, indicating that cryptolepine inhibits the stemness of CRC cells. Additionally, cryptolepine inhibited WNT3a-induced epithelial-to-mesenchymal transition by reducing the expression of SNAI1 and TWIST1 genes. In a wound healing assay, cryptolepine was found to suppress cell migration under unstimulated and WNT3a-stimulated conditions. Moreover, cryptolepine downregulated WNT3a-induced expression of MMP2 and MMP9 genes, which are involved in cancer cell invasion. Altogether, cryptolepine suppresses CRC cell proliferation, stemness, and metastatic properties by inhibiting WNT3a-mediated activation of the WNT/β-catenin signaling pathway. These findings provide a rationale for considering cryptolepine as a potential WNT inhibitor in CRC.

26 March 2023 in Genes
Verified
Journal Article
Open access
PDF file
KFKwadwo Fosu
Kwadwo Fosu
JQJude Tetteh Quarshie
Jude Tetteh Quarshie
KSKwabena Amofa Nketia Sarpong
Kwabena Amofa Nketia Sarpong
AAAnastasia Rosebud Aikins
Anastasia Rosebud Aikins
An inverse comorbidity has been observed between Down syndrome (DS) and solid tumors such as breast and lung cancers, and it is posited that the overexpression of genes within the Down Syndrome Critical Region (DSCR) of human chromosome 21 may account for this phenomenon. By analyzing publicly available DS mouse model transcriptomics data, we aimed to identify DSCR genes that may protect against human breast and lung cancers. Gene expression analyses with GEPIA2 and UALCAN showed that DSCR genes ETS2 and RCAN1 are significantly downregulated in breast and lung cancers, and their expression levels are higher in triple-negative compared to luminal and HER2-positive breast cancers. KM Plotter showed that low levels of ETS2 and RCAN1 are associated with poor survival outcomes in breast and lung cancers. Correlation analyses using OncoDB revealed that both genes are positively correlated in breast and lung cancers, suggesting that they are co-expressed and perhaps have complementary functions. Functional enrichment analyses using LinkedOmics also demonstrated that ETS2 and RCAN1 expression correlates with T-cell receptor signaling, regulation of immunological synapses, TGF-β signaling, EGFR signaling, IFN-γ signaling, TNF signaling, angiogenesis, and the p53 pathway. Altogether, ETS2 and RCAN1 may be essential for the development of breast and lung cancers. Experimental validation of their biological functions may further unravel their roles in DS and breast and lung cancers.

19 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAlberta Serwaa
Alberta Serwaa
FOFatima Oyawoye
Fatima Oyawoye
IOIrene Amoakoh Owusu
Irene Amoakoh Owusu
DDDaniel Dosoo
Daniel Dosoo
AMAaron Adom Manu
Aaron Adom Manu
AAAnastasia Rosebud Aikins
Anastasia Rosebud Aikins
The coronavirus disease 2019 (COVID-19) reportedly exacerbates cancer outcomes. However, how COVID-19 influences cancer prognosis and development remains poorly understood. Here, we investigated the effect of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), the etiological agent of COVID-19, on cellular cancer phenotypes the expression of cancer-related markers, and various proinflammatory cytokines. We infected prostate (22RV1) and colorectal (DLD-1) cancer cell lines, which express angiotensin-converting enzyme 2 (ACE2), with spike pseudovirus (sPV) and laboratory stocks of live SARS-CoV-2 viruses. After infection, we quantified changes in the cellular cancer phenotypes, the gene expression levels of some cancer markers, including Ki-67, BCL-2, VIM, MMP9, and VEGF, and proinflammatory cytokines. Phenotypic analysis was performed using MTT and wound healing assays, whereas gene expression analysis was carried out using real-time quantitative PCR (RT-qPCR). We show that SARS-CoV-2 infection impacts several key cellular pathways involved in cell growth, apoptosis, and migration, in prostate and colorectal cancer cells. Our results suggest that SARS-CoV-2 infection does influence various cancer cellular phenotypes and expression of molecular cancer markers and proinflammatory cytokines, albeit in a cell-type-specific manner. Our findings hint at the need for further studies and could have implications for evaluating the impact of other viruses on cancer progression.

11 November 2024 in Natural Product Communications
Verified
Journal Article
Open access
KFKwadwo Fosu
Kwadwo Fosu
JQJude Tetteh Quarshie
Jude Tetteh Quarshie
NONicholas Awuku Offei
Nicholas Awuku Offei
ASAlberta Serwaa
Alberta Serwaa
BTBernardine Tuah
Bernardine Tuah
AAAnastasia Rosebud Aikins
Anastasia Rosebud Aikins
Background: Triple-negative breast cancer (TNBC) remains a significant clinical challenge due to its aggressive nature and lack of targeted therapies. In TNBC, inflammation contributes to tumour progression by promoting cell proliferation, survival, and migration. It may be triggered by cytokines such as TNF-α or chemotherapeutic agents such as doxorubicin (DOX). Thus, identifying agents that suppress inflammation in TNBC is of prime interest. Caffeic acid phenethyl ester (CAPE) is a naturally occurring anti-inflammatory compound that exhibits selective cytotoxicity against some cancer cells. However, its impact on cytokine or chemotherapy induced inflammation in TNBC has not yet been explored. Aim: This study aimed to investigate the effects of CAPE on TNF-α- or DOX-induced inflammation and metastatic markers in TNBC. Methods: The effects of CAPE and DOX on TNBC cell viability and migration were assessed using the MTT and wound healing assays, respectively. The effect of CAPE on the expression of pro-inflammatory cytokines, epithelial-mesenchymal transition (EMT) markers, and tumour invasion markers was evaluated using RT-qPCR. Results: CAPE inhibited TNF-α-induced proliferation and migration of TNBC cells. CAPE also suppressed TNF-α- and DOX-induced upregulation of NF-κB-regulated pro-inflammatory genes, IL-1B, IL-6, IL-8, and TNF-α, corroborating the evidence that CAPE suppresses NF-κB signalling. Additionally, CAPE suppressed EMT in TNF-α–stimulated and DOX-treated cells by downregulating vimentin and VCAM1. Furthermore, CAPE reduced the expression of the cancer invasion markers MMP2 and MMP9. Conclusions: We demonstrated the anticancer potential of CAPE and its ability to suppress cytokine and chemotherapy-induced inflammation. This study offers novel insights into the role of CAPE in suppressing inflammation and metastasis markers in TNBC, specifically in the context of TNF-α and DOX-induced NF-κB signalling. These findings underscore the urgent need to further study CAPE as a possible adjuvant for treating patients with TNBC, especially those undergoing chemotherapy.

2 May 2025 in Cancer Medicine
Verified
Journal Article
Open access
EAEmmanuel Owusu Ansah
Emmanuel Owusu Ansah
FKFoster Kyei
Foster Kyei
COCaleb Frimpong Opoku
Caleb Frimpong Opoku
ADAndrews Danquah
Andrews Danquah
KFKwadwo Fosu
Kwadwo Fosu
DADaniel Sakyi Agyirifo
Daniel Sakyi Agyirifo
Background: Blood lipids are implicated in the development of breast cancer (BC), though the genetic connection remains unclear, particularly in African populations. Observational studies on this topic are limited by confounding factors and reverse causation, potentially affecting the reliability of findings. Methods: We applied univariate and multivariable two‐sample Mendelian randomization to assess the causal association between blood lipids (total cholesterol [TC], high‐density lipoprotein [HDL], low‐density lipoprotein [LDL], and triglycerides [TG]) and BC. Summary‐level data for lipid traits were sourced from the Africa Wits‐INDEPTH partnership for Genomic Research (AWI‐Gen) ( N = 10,603 women). BC data were obtained from the largest genome‐wide association study of BC in African women, comprising 18,034 BC cases and 22,104 controls. Results: Our analysis revealed that genetically predicted TG was associated with a decreased BC risk (OR = 0.73, 95% CI = 0.56–0.95, p = 0.018. In contrast, no significant associations were found between TC, HDL, or LDL levels and BC risk: TC (OR = 1.04, 95% CI = 0.93–1.18, p = 0.467), HDL (OR = 1.29, 95% CI = 0.93–1.79, p = 0.121), and LDL (OR = 1.04, 95% CI = 0.90–1.20, p = 0.577). After adjusting for the effects of other lipid traits, the association between TG and BC was attenuated, and no associations were observed for TC, HDL, or LDL. No causal relationship was found between lipid traits and BC subtypes. Conclusions: This study provides evidence that elevated triglycerides may be associated with a reduced risk of BC, whereas no significant associations were observed for TC, HDL, or LDL. Further research is needed to better understand the underlying mechanisms and potential clinical implications of these findings.